CompletedNot Applicable

Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration

France100 participantsStarted 2018-11-26

Plain-language summary

Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment. * Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months * Signature of informed consent * Affiliation to the French social security system Exclusion Criteria: * Pregnant or nursing patient (a urinary pregnancy test will be performed) * Systemic treatment with anti-VEGF * Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye. * Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis. * Diabetes Mellitus * High Myopia * Simultaneous participation in another clinical research protocol in exudative AMD * Person under guardianship, under curatorship, deprived of liberty

What they're measuring

Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months

Timeframe: At Month 3

Trial details

NCT IDNCT03630562

SponsorCentre Hospitalier Universitaire de Nice

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-01-12

View on ClinicalTrials.gov More Age Related Macular Degeneration trials